Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Molibresib (GSK525762) 是一种 BET 溴结构域抑制剂,IC50为32.5在42.5 nM 之间。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 428 | 现货 | ||
2 mg | ¥ 617 | 现货 | ||
5 mg | ¥ 913 | 现货 | ||
10 mg | ¥ 1,630 | 现货 | ||
25 mg | ¥ 2,780 | 现货 | ||
50 mg | ¥ 4,170 | 现货 | ||
100 mg | ¥ 5,930 | 现货 | ||
200 mg | ¥ 8,230 | 现货 | ||
500 mg | ¥ 12,200 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 851 | 现货 |
产品描述 | Molibresib (GSK525762) is an inhibitor of BET proteins (IC50: about 35 nM). |
靶点活性 | BET proteins:35 nM |
体外活性 | 连续两天每日注射两次I-BET-762,可使小鼠免于脓毒症造成的死亡.I-BET-762可防止细菌诱导的脓毒病和脂多糖诱导的内毒素休克.脂多糖注射后1.5 h,I-BET-762可治愈小鼠.在实验性自身免疫性脑脊髓炎小鼠模型中,I-BET-762早期处理可抑制Th1分化的2D2 T细胞诱发神经性炎症的能力. |
体内活性 | 在分化的第2天,I-BET-762处理可改变CD4+T细胞的细胞因子产生,使一些抗炎基因产物的表达上调,并使一些促炎细胞因子的表达下调。I-BET-762抑制溴区和额外的末端结构域的蛋白和BRD2/3/4结合到BET的串联溴区(Kd:50.5-61.3 nM), 在FRET分析中,置换BET串联溴区一种四乙酰化的H4肽(IC50:32.5-42.5 nM)。 |
激酶实验 | Fluorescence resonance energy transfer (FRET) titrations: Fluorescence resonance energy transfer (FRET) titrations. I-BET is titrated against BRD2 (200 nM), BRD3 (100 nM) and BRD4 (50 nM) in 50 mM HEPES pH7.5, 50 mM NaCl, 0.5 mM CHAPS in the presence of tetra-acetylated Histone H4 peptide (200 nM). After equilibrating for 1 hour, the bromodomain protein : peptide interaction is detected using FRET following the addition of 2 nM Europium cryptate labelled streptavidin and 10 nM XL-665-labelled anti-6His antibody in assay buffer containing 0.05% (v/v) BSA and 400 mM KF. Plates are read using an Envision Plate reader (excitation 320 nm, emission 615 nm and 665 nm). |
细胞实验 | CD4+ T cells are isolated from lymph nodes and spleens of 10- to 12-wk old mice and activated with plate bound anti-CD3 and anti-CD28 antibodies in the presence of indicated cytokines. I-BET-762 compounds is included during the 60–72 h of initial activation. Over the course of 5 d of T-cell culture and expansion, the compounds is diluted 12-fold relative to the starting concentrations.(Only for Reference) |
别名 | GSK 525762A, GSK525762, (4S)-6-(4-氯苯基)-N-乙基-8-甲氧基-1-甲基-4H-[1,2,4]三唑并[4,3-a][1,4]苯并二氮杂卓-4-乙酰胺, I-BET 762 |
分子量 | 423.9 |
分子式 | C22H22ClN5O2 |
CAS No. | 1260907-17-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 39 mg/mL (92 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 78 mg/mL (184 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.359 mL | 11.7952 mL | 23.5905 mL | 58.9762 mL |
5 mM | 0.4718 mL | 2.359 mL | 4.7181 mL | 11.7952 mL | |
10 mM | 0.2359 mL | 1.1795 mL | 2.359 mL | 5.8976 mL | |
20 mM | 0.118 mL | 0.5898 mL | 1.1795 mL | 2.9488 mL | |
50 mM | 0.0472 mL | 0.2359 mL | 0.4718 mL | 1.1795 mL | |
DMSO | 100 mM | 0.0236 mL | 0.118 mL | 0.2359 mL | 0.5898 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Molibresib 1260907-17-2 Chromatin/Epigenetic Epigenetic Reader Domain GSK525762A Inhibitor GSK 525762A GSK525762 inhibit GSK-525762 I-BET-762 (4S)-6-(4-氯苯基)-N-乙基-8-甲氧基-1-甲基-4H-[1,2,4]三唑并[4,3-a][1,4]苯并二氮杂卓-4-乙酰胺 I-BET762 GSK 525762 I-BET 762 inhibitor